These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 28391165

  • 1. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway.
    Zheng G, Shen Z, Chen H, Liu J, Jiang K, Fan L, Jia L, Shao J.
    Biomed Pharmacother; 2017 Jun; 90():437-445. PubMed ID: 28391165
    [Abstract] [Full Text] [Related]

  • 2. Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent.
    Zheng N, Chen J, Liu W, Wang J, Liu J, Jia L.
    Biomed Pharmacother; 2017 Jun; 90():339-349. PubMed ID: 28376402
    [Abstract] [Full Text] [Related]

  • 3. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M, Zhou LY, Xu N, An Q.
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [Abstract] [Full Text] [Related]

  • 4. SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/ mTOR Signaling Pathways.
    Zhou J, Luo J, Gan R, Zhi L, Zhou H, Lv M, Huang Y, Liang G.
    Recent Pat Anticancer Drug Discov; 2024 Jun; 19(4):543-555. PubMed ID: 38305308
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways.
    Pan J, Cai X, Zheng X, Zhu X, Feng J, Wang X.
    Tissue Cell; 2022 Apr; 75():101740. PubMed ID: 35101688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents.
    Wang J, Chen J, Zhu Y, Zheng N, Liu J, Xiao Y, Lu Y, Dong H, Xie J, Yu S, Shao J, Jia L.
    Biomed Pharmacother; 2016 Mar; 78():291-300. PubMed ID: 26898454
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Wang J, Ma S, Chen X, Zhang S, Wang Z, Mei Q.
    Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
    [Abstract] [Full Text] [Related]

  • 16. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 May 31; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.